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ABSTRACT 
MECHANSIMS FOR SURVIVAL AND DRUG RESISTANCE IN CANCER CELLS 
By 
Matthew Utter 
Advisor: Dr. David A. Foster 
PART I 
 Prostate cells are hormonally driven to grow and divide. Typical treatments for 
prostate cancer involve blocking the hormone androgen from activating the androgen 
receptor (AR) and thus inhibit growth and proliferation of the cancer. Androgen deprivation 
therapy (ADT) can lead to the selection of cancer cells that grow and divide independently 
of androgen receptor activation. Prostate cancer cells that are insensitive to androgens 
commonly display metastatic phenotypes and reduced long-term survival of patients. In 
this study, we provide evidence that androgen-insensitive prostate cancer cells have 
elevated phospholipase D (PLD) activity relative to the androgen-sensitive prostate cancer 
cells. PLD activity has been linked with promoting survival in many human cancer cell 
lines; and consistent with the previous studies, suppression of PLD activity in the prostate 
cancer cells resulted in apoptotic cell death. Of significance, suppressing the elevated 
PLD activity in the androgen-insensitive prostate cancer lines also blocked the ability of 
these cells to migrate and invade Matrigel™. Since survival signals are generally an early 
event in tumorigenesis, the apparent coupling of survival and metastatic phenotypes 
implies that metastasis could be an earlier event in malignant prostate cancer than 
generally thought. Resistance to ADT appears to involve an elevation in PLD activity 
providing a survival program that is coupled to migration and invasion. Interruption of this 
	   v	  
pathway could provide a therapeutic strategy for treating androgen-insensitive prostate 
cancer. 
 
PART II  
 Inhibiting the mammalian Target of Rapamycin Complex 1 (mTORC1) with 
rapamycin while suppressing Transforming Growth Factor-β (TGF-β) signaling induces 
apoptosis in many cancer cells.  Some cancer cells, though, are resistant to the apoptotic 
effects of rapamycin treatment in the absence of TGF-β signaling.  Both mTORC1 and 
TGF-β are upstream effectors of Retinoblastoma protein (Rb), a key regulatory protein 
involved in cell cycle progression from G1 to S-phase.  We found that rapamycin-resistant 
cell lines had a nonfunctional Rb protein and a deleted CDKN2A gene.  When Rb function 
was restored in the rapamycin resistant cells, apoptosis was induced upon rapamycin 
treatment.  When Rb was knocked down in cells with deleted CDKN2A, the cells gained 
the rapamycin resistant phenotype. The common downstream target of Rb and CDKN2A 
is E2F1 and inhibition of E2F1 sensitizes the cell to the apoptotic effects of rapamycin. 
The data suggest that Rb and CDKN2A may be part of compensatory pathways and that 
the interruption of both pathways is necessary to confer resistance to mTORC1 inhibition.  
Resistance to mTORC1 inhibition by rapamycin, a downstream target of PLD, appears to 
involve E2F1 and implicates the involvement of CDKN2A and Rb at the G1-S phase 
boundary of the cell cycle as a point of therapeutic intervention. 
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Prostate cancer and androgen deprivation therapy 
Prostate cancer is the most commonly diagnosed cancer in American men and is 
the second leading cause of cancer death amongst this demographic.1 The cells of the 
prostate, especially the epithelial cells, are characterized by strong androgen receptor 
(AR) signaling.2 Prostate cancer growth and proliferation is often driven by activation of 
the androgen receptor. In 1966, Charles Huggins was awarded the Nobel Prize for his 
work in demonstrating that castration or estrogen administration would reduce the prostate 
carcinoma size.3 In 1977, the Nobel Prize was awarded to Andrzej Schally and Roger 
Guillemin for their discovery of the role of gonadotropin releasing hormone in reproduction 
and hormone regulation.4,5 These two discoveries led to the most common treatment for 
prostate cancer, androgen deprivation therapy (ADT), a treatment that often leads to 
remission but can lead to relapse that is not only ADT resistant, but also much more 
aggressive. 
Androgens are produced mainly in the form of testosterone. When testosterone has 
entered the cell, it is converted to dihydrotestosterone (DHT) by 5α-reductase. Prior to 
androgen receptor binding to DHT, it is in an inactive state. The inactive state is bound to 
several heat shock proteins. When the AR binds to DHT, it disassociates from the heat 
shock proteins, interacts with co-activators, and dimerizes to become the active 
homodimer. This homodimer then translocates from the cytoplasm to the nucleus, binds to 
the androgen response element, and activates transcription of those particular genes (Fig. 
1.1).6 The androgen receptor can also be activated to a lesser degree by adrenal 




One common treatment for prostate cancer is androgen ablation. This can be 
achieved surgically with an orchiectomy or with drugs. Gonadotropin releasing hormone 
agonists, which cause an initial surge of testosterone but then eventually block the 
production of testosterone, and androgen receptor antagonists block the binding of 
testosterone and DHT to the androgen receptor. The antagonists could also help in 
blocking AR activation from adrenal androgens which are unaffected by androgen ablation 
from surgery or hormone agonists.8 
Figure	  1.1-­‐	  Androgen	  receptor	  activation.6	  Testosterone	  (T)	  bound	  to	  sex	  hormone-­‐binding	  globulin	  
(SHBG)	   is	   released	   and	   enters	   the	   prostate	   cell.	   Testosterone	   is	   reduced	   by	   5a-­‐reductase	   to	  
dihydrotestosterone	  (DHT)	  and	  binds	  to	  the	  androgen	  receptor	  (AR),	  releasing	  it	  from	  the	  heat	  shock	  
proteins	   (HSP).	   The	   AR	   then	   translocates	   to	   the	   nucleus,	   binds	   to	   its	   cofactors	   and	   begins	  




Many tumors initially regress due to androgen ablation therapy. However, often 
these tumors eventually grow back in an androgen-refractory manner.9 This may be 
caused by the selection pressure placed on the cells due to the androgen ablation 
therapy. The cells that are androgen-dependent go through apoptosis causing the initial 
tumor regression.  Then, the only prostate cancer cells to survive are androgen-refractory 
and grow to form the new tumor.10 The prospects for successful treatment of prostate 
cancer after it has become androgen-refractory are very low.11  
A common mechanism for promoting resistance to androgen deprivation is 
persistent androgen receptor signaling.12 Genetic alterations at the androgen receptor 
locus such as mutations in the ligand‑binding domain or amplification of the androgen 
receptor gene have been suggested to promote androgen receptor signals under 
conditions of low serum testosterone.13 
Another route to androgen independence is activation of the phosphatidylinositol‑ 
3‑kinase (PI3K)‑AKT‑mTOR (mammalian target of rapamycin) signaling pathway.13 This 
pathway is clearly emerging as an important signaling node that promotes androgen 
resistance and stimulates tumor growth in the setting of reduced levels of testosterone. 
This pathway appears to be altered at the genomic and transcriptional level in most 
metastatic prostate cancers.14,15,16 There are several points of therapeutic intervention for 
prostate cancers where the PI3K-AKT-mTOR signaling pathway is promoting survival and 
metastasis.13 
Phospholipase D 
An under-appreciated component of the intra-cellular signals leading to the 
activation of mTOR is phospholipase D (PLD).17  PLD generates a metabolite 
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phosphatidic acid (PA)18 that is required for the stability of the mTOR complexes – 
mTORC1 and mTORC2.19   
PLD superfamily members have been discovered in a wide range of species from 
bacteria and yeast to plants and animals. PLD is best known to hydrolyze 
phosphotidylcholine to the lipid second messenger, PA, and has been implicated in 
processes that include membrane vesicle trafficking, cytoskeletal reorganization, and cell 
migration.20,21,22 In the last two decades, PLD has also been shown to be activated in 
response to oncogenic and mitogenic signals. PLD has been shown to have elevated 
activity in the presence of epidermal growth factor, vascular endothelial growth factor, 
Figure	  1.2-­‐	  Domain	  alignment	  of	  PLD	  and	  related	  family	  members.30	  The	  active	  HKD	  domain	  for	  
PLD	  remains	  conserved	  across	  species	  from	  human	  to	  yeast,	  plants	  and	  bacteria.	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insulin, insulin-like growth factor-1, v-Src, Ras, and v-Raf.23,24,25,26,27,28,29  
Mammalian PLD enzymes contain phox and pleckstrin homology (PX and PH) 
domains to locate them to lipid membranes and four conserved regions (I-IV). Two of 
these regions (II and IV) contain a highly conserved charged motif called the HKD motifs, 
HxK(x)4D(x)6GSxN. The HKD domains are completely conserved across species 
suggesting a vital role in the catalytic activity of PLD (Fig. 1.2).30 Both domains appear to 
be necessary for the catalytic activity of PLD.31 It was proposed that the mechanism 
involves a two-stage ping pong reaction between the two HKD domains. A phosphatidyl-
Figure	  1.3-­‐	  PLD-­‐catalyzed	  hydrolysis	  and	  transphosphatidylation.30	  The	  phosphotidylcholine	  (PC)	  binds	  
to	   one	   of	   the	   catalytic	   histidines	   to	   form	   the	   phosphatidyl-­‐	   PLD	   intermediate.	   The	   product	   of	  
phosphatidic	   acid	   (PA)	   which	   is	   released	   via	   hydrolysis	   while	   a	   phosphatidyl	   alcohol	   is	   released	   via	  









PLD intermediate is formed followed by a hydrolysis or transphosphatidylation reaction as 
shown in Fig. 1.3.32 The histidine residue from one HKD domain acts as a nucleophile that 
attacks the phosphodiester bond to form the phosphatidyl-PLD intermediate. The histidine 
of the second HKD domain acts as a general acid and protonates the choline leaving 
group. The second half of the reaction uses water or a primary alcohol to hydrolyze the 
phosphatidyl-PLD intermediate and release PA or a phosphatidyl alcohol, respectively.33 
The use of a primary alcohol to produce a phosphatidyl alcohol forms the basis for 
detecting and measuring PLD activity used in this project. 
 In mammalian cells two isoforms of phospholipase D that are found to associate 
with membrane surfaces in the cytoplasm exist, PLD1 and PLD2. Dysregulation of PLD2 
tends to be more correlated with cancer 
than that of PLD1 and they appear to be 
differently regulated.34 Both are 
dependent on phosphatidylinositol 4,5-
bisphosphate for activation but PLD1 
activity is also stimulated by ADP 
ribosylation factor (ARF), Rho family 
GTP-binding proteins and protein kinase 
C.30 The activation of PLD2 has been 
less well characterized. 
 Phospholipase D hydrolyzes PC 
to produce choline and PA. Choline is 
present in cells in abundance and is not 
Figure	  1.4-­‐	  Phosphatidic	  acid	  signaling.17	  (A)	  PA	  can	  
be	   produced	   by	   diacylglycerol	   (DG)	   kinase,	  
lysophosphatidic	   acid	   acyl	   transferase	   (LPAAT)	   or	  
PLD.	   (B)	   PA	   as	   lipid	   second	   messenger	   has	   been	  




believed to be significant in cell signaling. PA, however, is considered to be a lipid second 
messenger. PA can be produced from diacylglycerol and lysophosphatidic acid as well as 
from PC. PA can be reversibly converted into the lipid second messengers diacylglycerol 
and lysophosphatidic acid (Fig. 1.4A). It is believed the effects from PLD are not from PA 
being converted to diacylglycerol and lysophosphatidic acid, but rather from PA interacting 
with its targets.17 
 PA has been implicated in targeting pathways involving Ras, Rho and Arf-
GTPases, an NADPH oxidase, vesicle formation, phosphatidylinositol-4-phosphate-5-
kinase, Raf, and mTOR (Fig. 1.4B).35,36,37 Of particular interest is the activation of the 
protein kinase mTOR, a central node in regulating cell cycle progression and cell 
growth.38,39 PA has been shown to be necessary for the activation of mTOR by stabilizing 
its association with the companion proteins RAPTOR and RICTOR.40 Interestingly, the 
upstream activator of mTOR, the small GTP-ase Rheb, was found to activate PLD1 in a 
GTP-dependent manner.41 This implicates PLD1 as being a key component of growth 
factor-mediated mTOR activation.  
Mammalian Target of Rapamycin 
Rapamycin is a macrolide antibiotic isolated from the bacteria Streptomyces 
hygroscopicus that was originally discovered on Easter Island, also known as Rapa Nui, 
from which the drug’s name is derived.42 In 1991, Michael Hall identified a protein in yeast 
involved in cell cycle arrest that was targeted by rapamycin.43 He named this protein 
Target of Rapamycin (TOR). A few years later David Sabatini had identified a similar 
protein in mammalian cells that he named rapamycin and FKBP12 target 1 (RAFT1).44 
This protein was found to have striking homology to TOR found in yeast and the name 
was eventually changed to mammalian target of rapamycin (mTOR). 
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The mammalian target of rapamycin is a protein kinase that regulates cell cycle 
progression and cell growth.38,39 There are two complexes of mTOR, complex 1 
(mTORC1) and complex 2 (mTORC2). mTORC1 is associated with the protein RAPTOR 
while mTORC2 is associated with the protein RICTOR. The companion proteins RAPTOR 
and RICTOR have been shown to be involved in substrate recognition. mTORC1 
phosphorylates eukaryotic initiation factor 4E (eIF4E)-binding protein 1 (4EBP1) and 
ribosomal subunit S6 kinase (S6K).46 4EBP1 inhibits eIF4E which prevents cap-dependent 
mRNA transcription. Phosphorylating 4EBP1 releases the inhibition and allows cap-
dependent transcription to proceed. Phosphorylated S6K phosphorylates ribosomal 
subunit S6 which is involved in protein translation. Activation of both of these mTORC1 
substrates activates protein transcription and translation which would be necessary for a 
Figure	   1.5-­‐	  mTORC1	   and	  mTORC2	   signaling	   targets.45	   The	   two	   complexes	   of	  mTOR	  have	  different	  
targets.	   The	   rapamycin	   sensitive	   mTORC1	   targets	   4E-­‐BP1	   and	   S6K	   which	   are	   involved	   in	   cap-­‐
dependent	   protein	   translation,	   cell	   growth	   and	   proliferation.	   The	   mostly	   rapamycin	   insensitive	  
mTORC2	  targets	  Akt,	  serum	  and	  glucocorticoid-­‐regulated	  kinase	  1	  and	  protein	  kinase	  C	  α	  which	  are	  
involved	  in	  cell	  proliferation,	  survival	  and	  actin	  cytoskeleton	  organization.	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growing and proliferating cell. mTORC2 has been implicated in activating Akt, serum and 
glucocorticoid-regulated kinase 1, and protein kinase C α.46 These proteins are involved in 
cellular pathways associated with cell survival and growth (Fig. 1.5).47  
mTORC1 is much more sensitive to acute rapamycin inhibition than mTORC2.48,49 
Rapamycin binds to the protein FKBP12 and subsequently binds to the FKBP12 
rapamycin binding (FRB) domain on mTOR. This prevents the association of mTOR with 
its companion protein RAPTOR or RICTOR. The FRB domain is highly conserved across 
species.50 It seems unlikely this domain was conserved to maintain sensitivity to an 
antibiotic. It has been shown, however, that the FRB domain binds PA and that this 
binding was necessary for the stability of the mTOR complexes and rapamycin competes 
with PA for binding mTOR.19,51 
It has been suggested that the differential effects of rapamycin are due to a 
difference in affinity of mTORC1 and mTORC2 to PA (Fig. 1.5).17 One a study 
demonstrated a greater disassociation rate constant for mTORC1 to mTOR and PA 
versus that of mTORC2 to mTOR and PA.49   PA has been demonstrated to be a 
necessary component for the activation of both mTORC1 and mTORC2, though not 
entirely sufficient to activate mTOR on its own.19,37,52  
Currently rapamycin is approved for preventing transplant rejection and for the 
treatment of lymphangioleiomyomatosis, a rare lung disease often marked with a mutation 
in the tuberous sclerosis complex gene (TSC2). TSC2 is an inhibitor of Rheb in which the 
inactivation of TSC2 leads to unregulated activation of mTORC1.53 Of interest to this work 
is the research on rapamycin as a treatment for cancer. The mTOR pathway has been 
found to be dysregulated in many human cancers and is considered an important node to 
target in the treatment of cancer.54 In fact in 2007, an analog of rapamycin, temsirolimus, 
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was approved for treatment of renal cell carcinoma. We believe the limited efficacy of 
rapamycin treatment in cancer is due to rapamycin having a cytostatic effect on cancer 
cells. Our lab, however, has shown that elevated doses of rapamycin (20 μM) in the 
absence of transforming growth factor-β (TGF-β) signaling is cytotoxic rather than 
cytostatic to cancer cells.55 
TGF-β signaling and Cell Cycle 
TGF-β is a bifunctional regulator that can either inhibit or stimulate cell proliferation 
depending on the context.56 TGF-β was originally isolated as a factor that would induce 
cellular transformation in selected fibroblast cell lines.57 TGF-β was also found to have 
growth inhibitory effects in African green monkey kidney cells58 and this growth inhibition 
is the best-characterized aspect of TGF-β signaling and the portion that will be focused 
upon in this report. TGF-β signaling is known to have a role in embryonic development, 
wound healing and angiogenesis. Defects in this signaling pathway have been implicated 
in diseases such as connective tissue disorders, fibrosis and cancer.59 
Activation of the TGF-β signaling pathway involves binding of the TGF-β receptor 
with the TGF-β ligand. This leads to the dimerization of the TGF-β receptor and 
autophosphorylation of the receptors. Activation leads to phosphorylation of the 
downstream targets Smad2 or Smad3. The Smads were found to be structurally similar to 
mothers against decapentaplegic (Mad) in Drosophila and sma (small worms) in C. 	  
elegans.60 The protein in mammalian cells was named as a portmanteau of sma and Mad 
and given the name Smad. When Smad 2 or Smad 3 is phosphorylated it will bind to its 
cofactor, Smad4. This complex will translocate to the nucleus and begin transcription of its 
target genes. One such gene is the gene for p27, a cyclin-dependent kinase (CDK) 
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inhibitor. p27 inhibits Cyclin E/CDK2 which, in turn, inhibits the retinoblastoma protein 
(Rb). Rb binds to E2F and when Rb is phosphorylated by Cyclin D/CDK4/6 and 
subsequently hyperphosphorylated by Cyclin E/CDK2 it will release E2F. E2F is a 
transcription factor that will transcribe the genes necessary for the transition from the first 
gap (G1) phase of the cell cycle to the synthesis (S) phase of the cell cycle.61  
Previously, our lab has described that the cytostatic versus cytotoxic effects of 
rapamycin treatment on cancer cells involved TGF-β signaling.55,62 When rapamycin is 
used at low doses, S6K phosphorylation is inhibited while mTORC1’s kinase activity 
Figure	  1.6-­‐	  Differential	  effects	  of	  rapamycin	  on	  cells	  depend	  on	  TGF-­‐β.	   (A)	   In	  the	  presence	  of	  TGF-­‐β,	  
rapamycin	  releases	  mTORC1’s	  inhibitory	  effect	  on	  the	  TGF-­‐	  β	  pathway.	  Transcription	  and	  translation	  of	  
p27	  leads	  to	   inhibition	  of	  cyclin	  E/	  CDK2.	  This	  releases	  the	  inhibition	  on	  Rb	  and	  E2F	  remains	  bound	  to	  
Rb.	  The	  cells	   arrest	   in	   late	  G1.	  (B)	   In	   the	  absence	  of	  TGF-­‐	  β	   signaling,	   cyclin	  E/	  CDK4/6	  can	   inhibit	  Rb	  
regardless	  of	  mTORC1	  status.	  Rb	  releases	  E2F	  and	  the	  cell	  progresses	  from	  late	  G1	  to	  S	  phase	  at	  which	  
point	  rapamycin	  treatment	  is	  cytotoxic.	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towards 4E-BP1 remains intact. However, at concentrations high enough to inhibit the 
phosphorylation of both S6K and 4E-BP1 in the presence of TGF-β, the effect is to arrest 
the cells in late G1 phase.63,64 Rapamycin inhibits mTORC1 and mTORC1 leads to the 
inhibition of the TGF-β pathway.65 When rapamycin is used, the inhibition of the TGF-β 
pathway is released and p27 inhibits Cyclin E/CDK2. Rb does not get 
hyperphosphorylated and E2F remains bound to Rb. The cell arrests in the late G1 phase 
of the cell cycle (Fig. 1.6A).55,66 
 When TGF-β signaling is shut down through inhibition of the TGF-β receptor, 
knockdown of Smad4 or simply depriving cells of serum, the effects of rapamycin 
treatment become cytotoxic. When rapamycin treatment inhibits mTORC1, its effect on 
the TGF-β pathway is negligible since the pathway is not active. Now there is no activation 
of p27 and Rb gets hyperphosphorylated, releases E2F and the cell progresses from G1 
to S-phase in the cell cycle (Fig. 1.6B). When the cells enter S-phase with mTORC1 
inactivated, the cells undergo apoptosis.63,65 
CDKN2A and its effects on E2F 
 The CDKN2A gene locus is the second most frequently mutated gene behind TP53 
in cancer cells.67 CDKN2A is a gene that transcribes the RNA for several proteins. The 
two best-studied products are p16INK4a and the other is p14ARF, a protein translated from a 
separate open reading frame giving it a completely different amino acid sequence.68 
P16INK4A is known to be a cyclin dependent kinase inhibitor that specifically inhibits 
CDK4/6. CDK4/6 when bound to Cyclin D is responsible for hypophosphorylating Rb and 
priming it for the hyperphosphorylation by Cyclin E/CDK2 that inactivates Rb. Rb will then 
release E2F, a transcription factor involved in transcribing genes involved in progressing 
cells from late G1 into the S phase of the cell cycle. 
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p14ARF is a distinctly different protein encoded by the same gene as p16INK4a. Since 
it is encoded by a different reading frame from p16INK4a, it has an entirely different amino 
acid sequence. It was named p14ARF for its molecular weight (14 kDa) and the fact that it 
is on an Alternate Reading Frame from p16INK4a. p14ARF is best characterized as an 
inhibitor of MDM2, itself an inhibitor of 
p53, the most commonly mutated 
gene found in cancers.69,70 p53 is also 
a transcription factor and leads to the 
transcription of p21, a cyclin 
dependent kinase inhibitor that 
inhibits CDK2, ultimately leading to 
activation of Rb and sequestration of 
E2F. This results in a cell cycle arrest 
at the late G1 – S boundary of the cell 
cycle. 
p14ARF has been found to not 
only have the indirect effect on E2F 
through MDM2 and p53, but also a 
direct effect through a negative 
feedback loop on E2F.71 One of the 
targets of transcription for E2F is the 
CDKN2A gene. p14ARF, in turn, will 
bind to E2F and prevent it from 
Figure	   1.7-­‐	   Both	  Rb	   and	  p14ARF	   directly	   inhibit	   E2F.	  A	  
transcription	   factor	   for	   CDKN2A	   is	   E2F.	   CDKN2A	   then	  
leads	   to	   the	   transcription	   of	   both	   p16INK4a	   and	   p14ARF.	  
p16INK4a	  is	  an	  inhibitor	  of	  CyclinD/CDK4/6	  which	  in	  turn	  
inhibits	   Rb.	   p14ARF	   inhibits	  MDM2	  which	   then	   releases	  
its	  inhibition	  of	  p53.	  This	  leads	  to	  transcription	  of	  p21,	  a	  
Cyclin	   E/CDK2	   inhibitor,	   again	   leading	   to	   inhibition	   of	  
Rb.	   p14ARF	   can	   also	   directly	   inhibit	   E2F	   forming	   a	  
negative	  feedback	  loop	  with	  E2F.	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binding to DNA and thus inhibit its transcriptional activity. The net effect of deleting both 
Rb and CDKN2A would release the inhibition on E2F and allow E2F to remain active. 
Project Rationale 
Most prostate cancers require androgens for proliferation and survival – and as a 
consequence are sensitive to androgen deprivation therapy.12 However, patients develop 
resistance to androgen deprivation and it is amongst these androgen resistant cancers 
that the most aggressive cancers emerge.72 A common mechanism for promoting 
resistance to ADT is persistent androgen receptor signaling.12 Genetic alterations at the 
androgen receptor locus such as mutations in the ligand‑binding domain or amplification 
of the androgen receptor gene have been suggested to promote androgen receptor 
signaling under conditions of low serum testosterone.13 
Another route to androgen independence is activation of the PI3K‑AKT‑mTOR 
signaling pathway.13 This pathway appears to be altered at the genomic and 
transcriptional levels in most metastatic prostate cancers.14,15,16 We previously reported 
that elevated PLD activity provided an mTOR-dependent survival signal in the absence of 
estrogen in estrogen receptor positive breast cancer cells.73,74 We also reported that PLD 
activity was elevated in estrogen receptor negative breast cancer cell lines deprived of 
serum and provided an mTOR-dependent survival signal.75 In addition to providing a 
survival signal, the elevated PLD activity in the estrogen receptor negative cells enhanced 
cell migration and invasion through Matrigel™, linking survival with metastatic 
phenotypes.75 Since survival signals are of necessity an early event in tumorigenesis to 
suppress default apoptotic programs, we proposed that the coupling of survival and 
migration signals in hormone-independent breast cancer cells promoted early 
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metastasis.75 We speculated that the androgen-independent prostate cancer may evade 
androgen deprivation induced apoptosis in a similar manner as estrogen receptor negative 
breast cancer had promoted survival through PLD. 
During the course of working with the prostate cancer cell lines, we noted that high 
dose rapamycin (20 µM) caused apoptosis in PC-3 and LNCaP cells in the absence of 
serum, and thus, TGF-β signaling. This was expected. In contrast, the DU145 cell line was 
resistant to the apoptotic effects of high dose rapamycin treatment in the absence of 
serum. Previously we had shown that MDA-MB-231 cells, a breast cancer cell line 
normally sensitive to the apoptotic effects of rapamycin, failed to undergo apoptosis after 
Rb was knocked down with siRNA.64 It was noted that DU145 cells also had a mutation 
that produced a nonfunctional Rb protein.76 We speculated that the loss of functional Rb 
was protecting the cells from the apoptotic effects of mTORC1 inhibition and began 













Chapter 2: Elevated phospholipase D activity in androgen-insensitive prostate 





Prostate cells are hormonally driven to grow and divide. Typical treatments for prostate 
cancer involve blocking the hormone androgen from activating the androgen receptor 
(AR) and thus inhibit growth and proliferation of the cancer. Androgen deprivation 
therapy can lead to the selection of cancer cells that grow and divide independently of 
androgen receptor activation. Prostate cancer cells that are insensitive to androgens 
commonly display metastatic phenotypes and reduced long-term survival of patients. In 
this study, we provide evidence that androgen-insensitive prostate cancer cells have 
elevated PLD activity relative to the androgen-sensitive prostate cancer cells. PLD 
activity has been linked with promoting survival in many human cancer cell lines; and 
consistent with the previous studies, suppression of PLD activity in the prostate cancer 
cells resulted in apoptotic cell death. Of significance, suppressing the elevated PLD 
activity in the androgen-insensitive prostate cancer lines also blocked the ability of these 
cells to migrate and invade Matrigel™. Since survival signals are generally an early 
event in tumorigenesis, the apparent coupling of survival and metastatic phenotypes 
implies that metastasis could be an earlier event in malignant prostate cancer than 
generally thought. This finding has implications for screening strategies designed to 






Phospholipase D activity is elevated in androgen-insensitive prostate cancer cell 
lines 
We previously demonstrated 
that there is elevated PLD activity in 
estrogen receptor negative breast 
cancer cells.74,75 The elevated PLD 
activity was largely restricted to cells 
deprived of serum75 – leading us to 
speculate that the elevated PLD 
activity was a stress response to the 
absence of serum. Since prostate 
cancer, like breast cancer, is largely a 
hormonally driven cancer,77 we 
wanted to evaluate the level of PLD 
activity in androgen responsive and 
androgen non-responsive prostate 
cancer cells. We looked at three 
prostate cancer cell lines – DU145 and 
PC3, which are androgen non-
responsive; and LNCaP, which are androgen responsive.78 PLD activity was evaluated 
in all three cell lines in both the presence of serum. As shown in Fig. 2.1, there was 
elevated PLD activity in the androgen refractory DU145 and PC-3 cells relative to the 
Figure	   2.1-­‐	   Phospholipase	   D	   activity	   is	   elevated	   in	  
androgen	   insensitive	   prostate	   cancer	   cell	   lines.	  
DU145,	  PC-­‐3	  and	  LNCaP	  cells	  were	  plated	  to	  a	  density	  
of	   200,000	   cells/35	   mm	   dish	   in	   complete	   media	  
containing	   10%	   serum	   or	   0%	   serum	   overnight.	   Cells	  
were	   then	   pre-­‐labeled	   for	   4	   hr	   with	   [3H]-­‐myristate	  
followed	  by	  the	  addition	  of	  0.8%	  1-­‐butanol	  for	  20	  min.	  
Phosphopholipase	   D	   activity	   was	   determined	   by	  
measuring	   the	   levels	   of	   the	   transphosphatidylation	  
product	   phosphatidylbutanol	   as	   described	   in	  
Materials	  and	  Methods.	  Experiments	  were	  performed	  
three	   times	   in	   duplicate.	   Error	   bars	   represent	  
standard	   error	   of	   mean	   (SEM).	   One-­‐way	   analysis	   of	  
variance	   was	   used	   to	   generate	   p	   values	   for	  
establishing	   the	   significance	   between	   LNCaP	   and	  
DU145	  or	  PC-­‐3	  under	  identical	  serum	  conditions	  (**,	  p	  
<	  0.05;	  ***,	  p	  <	  0.01).	  No	  significance	  was	  determined	  
for	  the	  difference	  in	  serum	  conditions	  within	  each	  cell	  




androgen responsive LNCaP cells. 
Unlike what was observed with breast 
and other cancer cells75, the level of 
PLD was elevated in both the 
presence and absence of serum – 
although the level in the absence of 
serum was slightly elevated relative to 
the cells in the presence of serum. 
Suppression of PLD activity in 
prostate cancer cell lines leads to 
apoptotic cell death 
We have previously reported 
that elevated PLD activity in a variety 
of cancer cells provides an mTOR-
dependent survival signal that 
suppresses apoptotic cell 
death.52,74,75,79 We therefore 
investigated the effect of suppressing 
PLD activity in the DU145 and PC-3 
Figure	   2.2-­‐	   Suppression	   of	   PLD	   activity	   in	   prostate	   cancer	   cell	   lines	   leads	   to	   apoptotic	   cell	   death.	  
DU145,	  PC-­‐3	  and	  LNCaP	  cells	  were	  plated	  at	  a	  density	  of	  50,000	  cells/35	  mm	  dish	  in	  complete	  media	  
containing	   10%	   serum.	  Cells	   were	   treated	  with	   PLD1	   and	  PLD2	   inhibitors	   (10	   μM)	   for	   the	   indicated	  
times.	   Cells	   were	   then	   harvested	   and	   cell	   viability	   was	  measured	   through	   trypan	   blue	   exclusion	   as	  
described	  in	  Materials	  and	  Methods.	  Cell	  lysates	  were	  used	  to	  probe	  for	  cleaved	  PARP	  by	  western	  blot	  
analysis	  (DU145	  and	  PC-­‐3	  at	  48	  hr,	  LNCaP	  at	  24	  hr).	  Experiments	  were	  performed	  in	   triplicate.	  Error	  
bars	  represent	  SEM.	  Paired	  t	  tests	  were	  performed	  using	  GraphPad	  Prism	  software	  (*,	  p	  <	  0.10;	  **,	  p	  <	  




cells. We have previously used inhibitors of PLD1 and PLD280,81 to suppress the effects 
of PLD in the nutrient induction of mTOR.82,83 Suppression of PLD activity in the 
androgen insensitive DU145 and PC3 cells with the PLD1 and PLD2 inhibitors led to a 
loss of cell viability as determined by the uptake of trypan blue (Fig. 2.2). Surprisingly, 
the androgen-responsive LNCaP cells were killed by the PLD inhibitors even better than 
the DU145 and PC-3 cells. This was in spite of relatively low levels of PLD activity 
compared with the DU145 and PC3 cells. As shown, the PLD inhibitors induced 
cleavage of the caspase 3 substrate PARP – indicating apoptotic cell death. Thus, PLD 
activity is providing a survival signal in the prostate cancer cells. While the PLD activity 
was substantially lower in the LNCaP cells relative to the DU145 cells, the LNCaP cells 
apparently need a basal level of PLD activity for survival. 
DU145 and PC-3 cells have higher migration and invasion than LNCaP cells 
In addition to promoting survival of breast cancer cells, elevated PLD activity also 
promoted cell migration and invasion of MatrigelTM.75 We therefore examined the ability 
of androgen refractory cancer cells, which have high levels of PLD activity, to migrate 
and invade MatrigelTM relative to the androgen responsive LNCaP cells, which have 
very low levels of PLD activity. As shown in Fig. 2.3A, both the DU145 and PC3 cells 
migrated and invaded MatrigelTM in transwell chamber assays. In contrast, the ability of 
LNCaP cells to migrate and invade MatrigelTM was negligible (Fig. 2.3A). We also 
employed a wound healing assay to evaluate the ability of the DU145, PC3 and LNCaP 
cells to migrate in culture. As shown in Fig. 2.3B, the DU145 and PC3 cells significantly 
migrated into the wound created by scraping the center of the culture dish. These data 
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reveal a correlation between the 
level of PLD activity in prostate	  
cancer cells and the ability to 
migrate and invade MatrigelTM. 
Inhibition of PLD in DU145 and 
PC-3 cells decreases migration 
and invasion 
The data presented in Fig. 
2.3 reveal a correlation between 
the level of PLD activity in prostate 
cancer cells and the ability to 
migrate in culture and invade 
MatrigelTM. We therefore 
examined the ability of DU145 and 
PC-3 to migrate and invade 
Matrigel™ in the presence of PLD 
Figure	  2.3-­‐	  DU145	  and	  PC-­‐3	  cells	  have	  higher	  migration	  and	  invasion	  than	  LNCaP	  cells.	  (A)	  DU145,	  PC-­‐3	  
and	  LNCaP	  cells	  were	  placed	  in	  the	  upper	  chamber	  for	  a	  transwell	  migration	  assay	  at	  a	  density	  of	  25,000	  
cells/6.5	  mm	  transwell	  chamber	  in	  complete	  media	  containing	  10%	  serum.	  Cells	  were	  allowed	  to	  migrate	  
through	   the	  pores	  of	   the	  membrane	  to	  the	   lower	  chamber	  for	  24	  hr	  and	  were	  fixed,	  stained	  and	  scored	  
under	   a	   microscope.	   Chambers	   with	   Matrigel™	   indicated	   invasion	   while	   chambers	   without	   Matrigel™	  
indicated	  migration.	  (B)	  DU145,	  PC-­‐3	  and	  LNCaP	  cells	  were	  plated	  at	  a	  density	  of	  100,000	  cells/16	  mm	  dish	  
in	  complete	  media	  containing	  10%	  serum.	  Cells	  were	  allowed	  to	  reach	  full	  confluence	  and	  a	  “wound	  gap”	  
was	   scratched	   through	   the	  monolayer	   of	   cells.	   The	  media	  was	   changed	   to	   fresh	  media	   containing	   10%	  
serum	  and	  the	  “wound	  gap”	  was	  allowed	  to	  close	  for	  24	  hr.	  The	  area	  of	  closure	  was	  quantified	  using	  the	  
MRI	  Wound	  Healing	   Tool	  macro	   for	   ImageJ.	   All	  experiments	  were	  performed	   at	   least	   twice	   in	   triplicate.	  
Error	  bars	  represent	  SEM.	  One-­‐way	  analysis	  of	  variance	  was	  used	  to	  generate	  p	  values	  for	  establishing	  the	  




	    
Figure	  2.4-­‐	  Inhibition	  of	  PLD	  in	  DU145	  and	  PC-­‐3	  cells	  decreases	  migration	  and	  invasion.	  (A)	  DU145	  
cells	  were	  plated	   for	  migration	  and	   invasion	   transwell	  assays	  as	   in	  Fig.	  2.3A	  and	   treated	  with	  PLD1	  
and	   PLD2	   inhibitors	   (10	   μM).	  After	   24	   hr	   cells	   that	  migrated	   through	   the	   pores	   of	   the	  membrane	  
were	   scored	   as	   in	   Fig.	   2.3A.	   (B)	   DU145	   and	   PC-­‐3	   cells	   were	   plated	   for	   wound	   healing	   assay	   and	  
treated	  with	  PLD1	  and	  PLD2	  inhibitors	  (10	  μM).	  A	  wound	  was	  scratched	  and	  allowed	  to	  fill	  in	  for	  24	  
hr	  at	  which	  time	  the	  degree	  of	  closure	  was	  determined	  as	  in	  Fig.	  2.3B.	  (C)	  DU145	  and	  PC-­‐3	  cells	  were	  
plated	   at	   a	   density	   of	  200,000	   cells/35	  mm	  dish	   in	  media	   containing	   10%	  serum	  and	  no	   antibiotic	  
overnight.	  Cells	  were	  transfected	  with	  negative	  control	  scrambled	  siRNA	  or	  siRNAs	  for	  PLD1	  and	  PLD2	  
as	  indicated.	  Five	  hours	  later	  the	  cells	  were	  shifted	  to	  complete	  media	  containing	  antibiotic.	  Seventy-­‐
two	  hours	  after	  transfection,	  cells	  were	  replated	  for	  wound	  healing	  assay	  as	  in	  Fig.	  2.3B.	  Twenty-­‐four	  
hours	   later	  cells	  were	  scored	  for	  wound	  healing,	  after	  which	  they	  were	  harvested	  and	  the	   levels	  of	  
PLD1	   and	   PLD2	  were	   determined	   by	  Western	   blot	   analysis.	   All	   data	   are	   representative	   of	   at	   least	  
three	  independent	  experiments.	  Error	  bars	  represent	  SEM.	  Paired	   t	  tests	  were	  performed	  as	   in	  Fig.	  




inhibitors or PLD knockdown. As shown in Fig. 2.4A, the ability of both DU145 and PC-3 
cells to migrate and invade MatrigelTM in transwell chamber assays was significantly 
suppressed by PLD inhibitors – especially the ability to invade MatrigelTM. Similarly, the 
ability of the DU145 and PC-3 cells to migrate in the wound-healing assay was 
suppressed by the PLD inhibitors (Fig. 2.4B). We also examined the impact of siRNA 
knockdown of both PLD1 and PLD2 in the wound-healing assay; and as shown in Fig. 
2.4C, the knockdown of PLD1 and PLD2 similarly suppressed migration of DU145 and 
PC-3 cells. Thus, the ability of the DU145 and PC-3 cells to migrate and invade 
MatrigelTM is dependent on the elevated PLD activity in these androgen insensitive 
prostate cancer cells. 
Overexpression of PLD2 in LNCaP cells increases migration and invasion 
We next asked whether elevated PLD activity in LNCaP cells would lead to 
increased migration and invasion of MatrigelTM. The LNCaP cells were transfected with 
plasmids that expresses HA-tagged PLD1 and PLD2. The level of PLD activity was 
elevated very slightly by PLD1, but PLD activity was substantially elevated in cells 
transfected with PLD2 (Fig. 2.5A). If PLD1 and PLD2 were introduced together into the 
LNCaP cells, the level of PLD activity was less than that observed with PLD2 alone (Fig. 
2.5A) – suggesting that elevated PLD1 expression might be inhibitory. As shown, in Fig 
2.5B, the HA-tagged PLD1 and PLD2 were both expressed in the LNCaP cells. The 
ability to migrate and invade MatrigelTM in transwell chambers was then examined; and 
as shown in Fig. 2.5C, LNCaP cells with elevated PLD2 expression and elevated PLD 
activity displayed an increased ability to migrate and invade MatrigelTM. Similarly, these 
cells also displayed increased migration in the wound-healing assay (Fig. 2.5D). These 
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data indicate that elevated PLD activity in prostate cancer cells is able to confer an 
increased ability to migrate and invade MatrigelTM. The greater impact of PLD2 relative 
to PLD1 on migration and invasion is similar to an observation we published several 
years ago where we reported that PLD2, but not PLD1, induced cell protrusions in rat 
fibroblasts transformed by the v-src oncogene.84 Thus, the migration and invasion 
properties may be more dependent on PLD2 than on PLD1.	   
Figure	   2.5-­‐	   Overexpression	   of	   PLD2	   in	   LNCaP	   cells	   increases	  migration	   and	   invasion.	   LNCaP	   cells	  
were	  plated	  for	  transfection	  as	  in	  Fig.	  2.4C	  with	  plasmids	  expressing	  empty	  vector	  or	  HA-­‐PLD1	  and/or	  
HA-­‐PLD2	  as	  indicated.	  After	  48	  hr	  cells	  were	  harvested	  and	  the	  relative	  levels	  of	  PLD	  activity	  (A)	  and	  
HA-­‐PLD1	   and	  HA-­‐PLD2	  protein	   levels	   (B)	  were	  determined.	   The	   levels	   of	  PLD	   activity	   in	   the	  DU145	  
and	   PC-­‐3	   cells	   were	   examined	   along	   with	   the	   transfected	   LNCaP	   cells	   for	   comparison.	   One-­‐way	  
analysis	  of	  variance	  was	  used	  to	  generate	  p	  values	  for	  establishing	  the	  significance	  between	  empty	  
vector	  LNCaP	  and	  PLD-­‐transfected	  LNCaPs,	  DU145	  and	  PC-­‐3	  cell	  lines	  (not	  significant	  (ns),	  p	  >	  0.10;	  *,	  
p	  <	  0.10;	  ***,	  p	  <	  0.01,	  ****,	  p	  <	  0.001).	  LNCaP	  cells	  were	  transfected	  with	  empty	  vector	  or	  vector	  
with	  HA-­‐PLD2	  as	  in	  (A)	  and	  then	  subjected	  to	  the	  transwell	  invasion	  and	  migration	  assays	  (C)	  and	  the	  
wound	   healing	   assays	   (D)	   as	   in	   Figs.	   2.3A	   and	   2.3B.	   All	   data	   are	   representative	   of	   at	   least	   three	  
independent	  experiments.	  Error	  bars	  represent	  SEM.	  Paired	  t	  tests	  were	  performed	  as	  in	  Fig.	  2.2	  (*,	  p	  





In this report, we have demonstrated that there are substantially higher levels of 
PLD activity in the androgen refractory DU145 and PC-3 prostate cancer cell lines 
relative to androgen responsive LNCaP prostate cancer cells. We reported previously 
that elevated PLD activity in human cancer cells promotes both survival 
signals17,73,74,85,86,87 and metastatic phenotypes.75,88 In this study with androgen 
refractory and androgen responsive prostate cancer cells, we find that the elevated PLD 
activity detected in the androgen refractory DU145 and PC-3 correlated with the ability 
to migrate and invade Matrigel.TM Surprisingly, inhibition of PLD killed all three cell lines 
– including the LNCaP cells which displayed low levels of PLD activity. Although the 
LNCaP cells are androgen responsive, these cells are not dependent on the presence 
of androgens for survival. They were however, dependent upon PLD for survival. Thus, 
the low level of PLD activity observed in the LNCaP cells was apparently needed for the 
survival of these cells. 
We previously proposed that elevated PLD activity in breast cancer cells 
represented a shift from hormone-dependent to hormone-independent cancer – where 
survival was originally dependent on estrogen, but then shifted to a dependence on 
PLD-generated PA for survival.75 This shift had the added consequence of enhancing 
cell migration and invasion that was dependent on PLD activity.75 The coupling of 
survival and migration signals has important implications for early detection and 
treatment.  Signals that suppress default apoptotic programs (survival signals) are 
generally early events in cancer.89,90 This is because driver mutations such as activating 
KRas mutations, in the absence of a survival signal, will lead to either apoptosis or 
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senescence.90,91 The observation that PLD is able to provide both survival and migration 
signals suggests that metastasis could be a much earlier event in breast and prostate 
cancers. The coupling of survival and migration could explain in part why prostate 
specific antigen tests and mammograms do not result in significant reductions in 
mortality.92 This point was made recently where breast cancer cells disseminated very 
early in mice.93,94,95 
We proposed previously that the coupling of survival and migration signals 
represented a stress response where the cells elevated their PLD activity in response to 
the stress of serum withdrawal.75 The rationale for this proposal was that at early stages 
of tumorigenesis prior to vascularization, emerging tumors would respond to the lack of 
growth factors and nutrients with a stress program that would suppress default apoptotic 
programs and promote migration to blood vessels where nutrients could be obtained. In 
this report, the PLD activity in prostate cancer cells was not dramatically elevated in 
response to serum withdrawal as was observed with breast cancer cells. However, 
suppressing PLD activity reduced migration and stimulated apoptosis – indicating that 















Chapter 3: Loss of Rb and CDKN2A confers resistance to mTORC1 inhibition in 




Inhibiting the mammalian Target of Rapamycin Complex 1 (mTORC1) with rapamycin 
while suppressing Tumor Growth Factor-β (TGF-β) signaling, pharmacologically or 
through serum withdrawal, induces apoptosis in many cancer cells.  Some cancer cells, 
though, are resistant to the apoptotic effects of rapamycin treatment in the absence of 
TGF-β signaling.  Both mTORC1 and TGF-β are upstream effectors of Retinoblastoma 
protein (Rb), a key regulatory protein involved in cell cycle progression from G1 to S-
phase.  We found that rapamycin-resistant cell lines had nonfunctional Rb and Alternate 
Reading Frame tumor suppressor (p14ARF) proteins.  When Rb function was restored in 
the rapamycin resistant cells, apoptosis was induced upon rapamycin treatment.  When 
Rb was knocked down in cells with mutated p14ARF, the cells gained the rapamycin 
resistant phenotype.  Our lab had previously demonstrated that rapamycin exerted its 
apoptotic effect when the cells were in S-phase. Cells with suppressed TGF-β signaling 
progressed into S-phase and upon mTORC1 inhibition apoptosis was induced. The 
cells with mutated Rb and p14ARF, however, arrested in G1-phase upon rapamycin 
treatment, even in the absence of TGF-β signaling.  Both Rb and p14ARF had been 
shown to be upstream effectors of E2F1, a transcription factor involved in G1 to S-
phase progression.  The data suggest that Rb and p14ARF may be part of compensatory 
pathways and that the interruption of both pathways is necessary to confer resistance to 






Cell lines with mutated Rb are resistant to rapamycin treatment 
 Previously, our lab had shown 
that high doses of rapamycin (20 uM) 
have a cytotoxic effect on cancer cell 
lines in the absence of TGF-β 
signaling.55,62 When TGF-β signaling 
is either blocked pharmacologically, 
genetically, or through removal of 
growth factors and serum, the cells 
are free to progress from late G1-
phase of the cell cycle into S-phase 
when mTORC1 activity is inhibited. 
The inhibition of mTORC1 with high 
dose rapamycin was shown to cause 
the cells to undergo apoptosis when 
this inhibition occurs during the S-
phase of the cell cycle.96 
While working with the prostate cancer cell lines PC-3, DU145 and LNCaP, it 
was noticed that high dose rapamycin induced apoptosis in the PC-3 and LNCaP cells 
but not in the DU145 cells. Additionally, our lab demonstrated that in the breast cancer 
cell line MDA-MB-231, the cells were resistant to the apoptotic effects of high dose 
rapamycin when Rb expression was knocked down.64 A commonality between these 
Figure	  3.1-­‐	  Cell	  lines	  with	  mutated	  Rb	  are	  resistant	  to	  
rapamycin	   treatment.	   	   MDA-­‐MB-­‐231,	   MCF-­‐7,	   NCI-­‐
H2228	   and	   DU145	   cells	   were	   plated	   to	   a	   density	   of	  
200,000	   cells/35	   mm	   dish	   in	   complete	   media	  
containing	  10%	  serum.	  Cells	  were	  then	  treated	  with	  20	  
uM	  rapamycin	  or	  DMSO	  in	  media	  with	  no	  serum.	  After	  
24	   hr,	   cells	   were	   harvested	   and	   cell	   viability	   was	  
measured	   through	   trypan	   blue	   exclusion	   as	   described	  
in	   Materials	   and	   Methods.	   Cell	   lysates	   were	   used	   to	  
probe	   for	   cleaved	   PARP	   by	   western	   blot	   analysis.	  
Experiments	   were	   performed	   in	   triplicate.	   Error	   bars	  
represent	   SEM.	   Paired	   t	   tests	   were	   performed	   using	  




two experiments was the lack of 
functional Rb as DU145 possess a 
mutated Rb that cannot bind to its 
downstream effector, E2F.76 It was 
surmised that the absence of functional 
Rb was imparting cancer cells with 
resistance to the cytotoxic effects of high 
dose rapamycin in the absence of TGF-β 
signaling. 
As shown in Fig. 3.1, the cell lines 
with wild type Rb, MDA-MB-231 and 
MCF-7, were found to be sensitive to the 
cytotoxic effects of high dose rapamycin 
treatment as indicated by an increase in 
nonviable cells and an increase in 
cleaved PARP levels, an early indicator 
of apoptosis, when compared to the cell 
lines with nonfunctional Rb, DU145 and 
NCI-H2228. 
Figure	   3.2-­‐	   Knockdown	   of	   Rb	   in	   rapamycin	  
sensitive	  cell	  lines	  leads	  to	  rapamycin	  resistance.	  
MDA-­‐MB-­‐231	   and	   MCF-­‐7	   cells	   were	   plated	   at	   a	  
density	   of	   200,000	   cells/35	   mm	   dish	   in	   media	  
containing	  10%	  serum	  and	  no	  antibiotic	  overnight.	  
Cells	   were	   transfected	   with	   negative	   control	  
scrambled	   siRNA	   or	   siRNA	   for	   Rb1	   as	   indicated.	  
Five	  hours	  later	  the	  cells	  were	  shifted	  to	  complete	  
media	   containing	   antibiotic.	   Cells	   were	   treated	  
with	   20	  μM	   rapamycin	   for	   24	   hr	   and	   48	  hr	   after	  
transfection,	   cells	   were	   harvested	   and	   levels	   of	  
cleaved	   PARP,	   Rb,	   phospho-­‐4EBP	   and	   total	   4EBP	  
were	  determined	  by	  Western	  blot.	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Knockdown of Rb in rapamycin 
sensitive cell lines leads to rapamycin 
resistance 
 The data in Fig. 3.1 suggested a 
correlation between the presence of the 
wild type Rb and sensitivity to the apoptotic 
effects of rapamycin. We then asked if we 
knocked down the expression levels of Rb, 
can we induce rapamycin resistance in 
these cell lines. As shown in Fig 3.2, when 
the Rb levels were knocked down in MDA-
MB-231 and MCF-7 cell lines, the cells 
demonstrated a resistance to the cytotoxic 
effects of rapamycin as indicated by the 
reduction of cleaved PARP levels. We 
measured rapamycin efficacy through 
phosphorylation of 4E-BP since our lab had 
previously shown that the apoptotic effects 
of high dose rapamycin necessitated the 
inhibition of the phosphorylation of 4E-BP 
by mTORC1.97  The data presented in Fig 
3.2 indicated that Rb plays a role in how 
high dose rapamycin kills cells in the 
Figure	   3.3-­‐	   Cell	   lines	   with	   mutated	   Rb	   are	  
sensitized	   to	   rapamycin	   treatment	   with	   wild-­‐
type	   Rb	   expression.	   DU145	   and	   NCI-­‐H2228	   cells	  
were	  plated	  at	  a	   density	   of	   200,000	   cells/35	  mm	  
dish	   in	   media	   containing	   10%	   serum	   and	   no	  
antibiotic	   overnight.	   Cells	   were	   transfected	   with	  
empty	   vector	   or	   a	   plasmid	   for	   HA-­‐Rb1	   as	  
indicated.	   Five	   hours	   later	   the	   cells	   were	   shifted	  
to	   complete	   media	   containing	   antibiotic.	   Cells	  
were	  treated	  with	  20	  μM	  rapamycin	  for	  24	  hr	  and	  
48	  hr	  after	  transfection,	  cells	  were	  harvested	  and	  
levels	   of	   cleaved	   PARP,	   Rb,	   phospho-­‐4EBP	   and	  
total	  4EBP	  were	  determined	  by	  Western	  blot.	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absence of TGF-β signaling.	   
Cell lines with mutated Rb are sensitized to rapamycin treatment with wild-type 
Rb expression 
 We next asked whether overexpression of wild type Rb in the cell lines with 
mutated Rb would sensitize the cells to the apoptotic effects of high dose rapamycin 
treatment. We inserted a plasmid that expressed wild type Rb in the cell lines DU145 
and NCI-H2228 and the cell lysates showed an increase in cleaved PARP levels when 
treated with rapamycin in the absence of serum in the media (Fig. 3.3). This indicated 
the cells were undergoing apoptosis and further reinforced the idea that Rb was 
involved with the cytotoxic effects of rapamycin treatment. 
 
 
Cell	  Line RB	  Mutation Rapamycin	  
lethality 
CDKN2A	  status 
DU145 Truncated No Deleted 
NCI-­‐H2228 Truncated No Deleted 
MDA-­‐MB-­‐231 WT Yes Deleted 
MCF-­‐7 WT Yes Deleted 
MDA-­‐MB-­‐468 Truncated Yes WT 
BT-­‐549 Truncated Yes WT 
 
 
Table	   3.1-­‐	   RB	   and	   CDKN2A	   mutations	   correlate	   with	   rapamycin	   lethality.	   Cell	   lines	   with	   both	  
nonfunctional	  Rb	  and	  CDKN2A	  are	  resistant	  to	  the	  apoptotic	  effects	  of	  rapamycin	  but	  can	  be	  sensitized	  
with	   the	   reintroduction	   of	   wild	   type	   Rb	   (DU145	   and	   NCI-­‐H2228).	   Cell	   lines	   with	   wild	   type	   Rb	   and	  
deleted	  CDKN2A	  are	  not	  resistant	  to	  the	  effects	  of	  rapamycin	  but	  can	  be	  made	  so	  by	  the	  knock	  down	  
of	  Rb	  (MDA-­‐MB-­‐231	  and	  MCF-­‐7).	  Cell	  lines	  with	  nonfunctional	  Rb	  and	  intact	  CDKN2A	  are	  not	  resistant	  





Inhibition of E2F1 sensitizes DU145 cells to rapamycin treatment 
 We then looked for other cancer cell lines that had mutations producing 
nonfunctional Rb and decided to look at the cell lines MDA-MB-468 and BT-549. 
Surprisingly, these cells were found to be unlike the DU145 and NCI-H2228 cells in that 
they underwent apoptosis when treated with high dose rapamycin in the absence of 
serum. We then looked at the mutations present in all six cell lines (MDA-MB-231, MCF- 
7, DU145, NCI-H2228, MDA-MB-468 and BT-549) (Table. 3.1).98,99 A pattern emerged 
in that the cell lines that had or gained rapamycin resistance had nonfunctional Rb and 
no CDKN2A. CDKN2A is a gene that produces two distinct proteins, p16INK4A and 
p14ARF. One of the functions of p14ARF is to inhibit E2F transcriptional activity, a similar 
function to that of Rb.71 We then asked if pharmacological inhibition of E2F activity could 
sensitize the resistant cell line, DU145 to 
the cytotoxic effects of rapamycin 
treatment. 
 We used the pharmacological 
inhibitor of E2F, HLM006474, to inhibit the 
transcriptional activity of E2F1. 
HLM006474 inhibits E2F by preventing 
E2F from binding to DNA and thus 
transcription of its targets is decreased.71 
One target of E2F1 transcription is E2F1 
itself and therefore E2F1 protein levels can 
Figure	  3.4-­‐	  Inhibition	  of	  E2F1	  sensitizes	  DU145	  
cells	   to	   rapamycin	   treatment.	   DU145	   cells	  
were	  plated	  as	  in	  Fig.	  3.1	  and	  then	  treated	  with	  
20	  µM	  rapamycin	  and	  40	  µM	  HLM006474	  for	  
24	  hr.	  Levels	  of	  cleaved	  PARP,	  E2F1,	  phosphor-­‐




be used as a read out for transcriptional activity of E2F.71  When E2F transcriptional 
activity was inhibited by HLM006474 in DU145 cells and then treated with high dose 
rapamycin in the absence of serum, we observed an increase in cleaved PARP, 
indicating apoptosis (Fig. 3.4).  
Discussion 
In this report, we have demonstrated that there is a correlation between the loss 
of wild type Rb and CDKN2A with the cell line’s resistance to high dose rapamycin 
treatment in the absence of TGF-β signaling. Previously we have shown that high dose 
rapamycin induces apoptosis in cancer cells when treated in the absence of TGF-β 
signaling.55,62 It has also been shown that inhibition of mTORC1 by rapamycin releases 
the inhibitory effect mTORC1 exercised over the TGF-β pathway.55 In the presence of 
TGF-β signaling this led to arrest in late G1-phase, while in the absence of TGF-β 
signaling, the cells progressed into S-phase.55 When cancer cells were treated with high 
dose rapamycin during S-phase, the rapamycin treatment was lethal.96 This implicated 
the proteins involved at the G1 – S phase transition to be important to rapamycin-
induced sensitivity to apoptosis, particularly Rb and E2F1. 
We have shown that the removal of functional Rb from cell lines already missing 
CDKN2A induced resistance to high dose rapamycin treatment. We have also shown 
that restoration of wild type Rb in the cell lines that were resistant to the apoptotic 
effects of rapamycin abrogated the resistance. This strongly implies that Rb plays a key 
role in imparting sensitivity to rapamycin. The canonical downstream effector for Rb is 
the transcription factor E2F1, which is coincidently a target of inhibition by p14ARF,71 one 
of the proteins transcribed from CDKN2A. 
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When we inhibited transcriptional activity of E2F1, we found that the cell lines 
that were once resistant to the apoptotic effects of high dose rapamycin treatment had 
become sensitive and underwent apoptosis. We believe the resistance to rapamycin-
induced apoptosis may be due to the unregulated transcriptional activity of E2F1. We 
believe the cells transition from G1-phase to S-phase and continue through the cell 
cycle unencumbered by E2F1 regulation by neither Rb nor p14ARF. Questions remain as 
to how mTORC1 inhibition by rapamycin induces apoptotic death when the cell is in the 
S-phase of the cell cycle, let alone how Rb and CDKN2A mutant cell lines evade that 
cell death. 
Since the Rb-CDKN2A double mutant cell lines survive when treated with 
rapamycin in the absence of TGF-β signaling, the cells are likely entering S-phase and 
continuing through to G2-phase. It is possible that Rb, and p16INK4a or p14ARF could be 
playing a role in S-phase that leads to apoptosis when mTORC1 is inhibited, in which 
the absence of that protein (Rb, and p16INK4a or p14ARF) either “blinds” the cell to the 
inhibition of mTORC1 or arrests the cells in S-phase. There is data suggesting that 
phosphorylated Rb is involved in the activation of nuclear c-Abl tyrosine kinase in the S-
phase of the cell cycle.100 There is additional data that demonstrates that CDK2 with 
Cyclin A, a transcriptional target of E2F1, can phosphorylate Akt.101 Phosphorylation of 
Akt leads to activation of survival signals.47 Further investigation into these interactions 






















 Based on the rationale presented in Chapter 1, we were able to demonstrate that 
elevated phospholipase D activity linked survival of androgen insensitive prostate 
cancer cell lines with the metastatic phenotypes of cell migration and invasion (Chapter 
2). Both the androgen insensitive and androgen sensitive cell lines required a minimum 
basal level of PLD activity to survive. The androgen insensitive cell lines had elevated 
PLD activity that increased migration and invasion, two phenotypes associated with 
metastasis. These metastatic phenotypes were abrogated when PLD activity was 
inhibited or PLD protein levels were knocked down. Additionally, overexpression of 
PLD2 in the androgen sensitive cell line increased its migration and invasion, implicating 
PLD2 rather than PLD1 as the driver for the metastatic phenotypes.  
 Zheng et al., had proposed that cells elevated their PLD activity in response to 
the stress of serum withdrawal. When there is poor vascularization and low levels of 
growth factors, the cells would activate a survival program to evade apoptosis and 
migrate to an environment where nutrients and growth factors could be found.75 While 
the prostate cancer cell lines did not show a dramatic increase in PLD activity in 
response to serum withdrawal, there was a marked difference in PLD activity between 
the androgen insensitive cell lines and the androgen sensitive cell line. This suggests 
the cells could be activating the PLD-mediated survival program in response to the 
withdrawal of androgens rather than serum. This would allow the cells to evade 
apoptosis due to androgen deprivation and then drive migration and invasion, thus 
making the cancer more deadly than androgen responsive prostate cancer.  
Linking survival to migration and invasion indicates that metastasis may be an 
earlier event during the progression of prostate cancer. Furthermore, coupling androgen 
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insensitivity to PLD-mediated survival, migration and invasion suggests that androgen 
deprivation therapy could drive low risk, localized prostate cancer to become deadly, 
androgen independent and metastatic prostate cancer. Several studies have already 
linked ADT to prostate cancer progressing to a more aggressive, metastatic prostate 
cancer.101,102,103 Targeting phospholipase D in androgen nonresponsive prostate cancer 
could be present as a viable therapeutic option. 
 Further work is warranted to elucidate which isoform of PLD is responsible for 
inducing the observed migration and invasion. Additional work needs to be done to 
determine the mechanism through which PLD increases migration and invasion. One 
mode may involve activation of mTORC2 for which the product of PLD, PA, is 
necessary to stabilize the complex. mTORC2 has been implicated in cytoskeleton 
organization, which would need to be activated in migrating cells.45,47 Other data could 
suggest PLD2 as the isoform involved in the actin reorganization.104 The PLD2 isoform 
tends to localize to the plasma membrane of the cell.105 This would place it in an ideal 
location for affecting cytoskeleton organization needed for migration. 
 In Chapter 3, we have shown that cell lines that are resistant to the apoptotic 
effects of mTORC1 inhibition with rapamycin in the absence of TGF-β signaling, evade 
apoptosis through the mutation of Rb and CDKN2A. Both Rb and the CDKN2A product 
p14ARF are direct inhibitors of E2F1. Inhibition of E2F1 sensitized the rapamycin 
resistant cells to the apoptotic effects of mTORC1 inhibition. The data suggest that 
understanding the particular mutations cancer possesses would drive what type 
treatment would be appropriate. This supports the current understanding of genotyping 
tumors and personalizing cancer treatment to the patient. 
	  
40	  
 Further work would be necessary to determine which target of CDKN2A’s 
absence is responsible for working synergistically with the Rb mutation to provide 
resistance to rapamycin treatment. Additional work would also need to be done to 
determine how this evasion works. Do the cells avoid S-phase arrest simply through 
uninhibited E2F1 transcripition? Does Rb play a role in rapamycin-induced lethality 
during S-phase?  
 The divergent phenotypic responses observed with DU145 when treated with 
PLD inhibitors versus rapamycin need to be reconciled. Both rapamycin and PLD 
inhibitors led to mTOR inactivation but PLD inhibitors caused the DU145 cells to 
undergo apoptosis while DU145 cells resisted the cytotoxic effects of rapamycin. A 
possible explanation for the observed differences may involve the differential effects 
rapamycin has on mTORC1 and mTORC2. The PA produced by PLD is necessary for 
the stability of both mTOR complexes and inhibition of PLD leads to a reduction in Akt 
activation, and therefore survival. Rapamycin inhibits the activity of mTORC1 while 
leaving mTORC2 largely unaffected. Akt-induced survival remains intact. Additionally, it 
has been shown that Cyclin A/CDK2 is also involved in activating Akt.101 Cyclin A is a 
target of E2F1, suggesting that active E2F1 can activate survival signals. This could 
explain why inhibition of E2F1 sensitizes DU145 cells to rapamycin treatment.  
  




















Cells and cell culture conditions 
The human cancer cell line lines DU145, PC-3, LNCaP, MDA-MB-231, MCF-7, NCI-
H2228, MDA-MB-468 and BT-549 cells were obtained from the American Tissue Type 
Culture Collection (ATCC). The DU145, MDA-MB-231, MCF-7, MDA-MB-468 and BT-
549 cancer cell lines were cultured in Delbecco’s modified Eagle’s medium (DMEM) 
(Sigma D6429) and supplemented with 10% Fetal Bovine Serum (FBS) (Sigma F4135). 
The human cancer cell lines PC-3 and NCI-H2228 were cultured in Roswell Park 
Memorial Institute medium (RPMI-1640) (Sigma R8758) and supplemented with 10% 
FBS. The human cancer cell line LNCaP was cultured in RPMI-1640 supplemented with 
10% FBS and 10 nM testosterone (Sigma T1500).  
Antibodies and reagents 
Reagents were obtained from the following sources: Antibodies against cleaved PARP 
(9541), HA-Tag (2367), PLD1 (3832), PLD2 (13904), Rb (9309), E2F-1 (3742), 
phospho-4EBP1 (T70) (9455) and total 4EBP1 (9452) were obtained from Cell 
Signaling; β-actin (60008) was obtained from ProteinTech; anti-mouse and anti-rabbit 
HRP conjugated secondary antibodies were obtained from Promega. Negative control 
scrambled siRNA (D-001810) and siRNAs targeted against PLD1 (L-009413), PLD2 (L-
005064) and Rb (L-003296) were obtained from Dharmacon. Lipofectamine RNAiMax 
(Invitrogen, 56532) was used for siRNA transfection. Plasmids with hemagglutinin (HA)-
tagged PLD1 (pCMV3 HA PLD1) (Sino Biological HG13850), HA-tagged PLD2 
(pcDNA3.1 HA PLD2) (gift from M. Frohman, SUNY Stony Brook) and HA-tagged Rb 
(pCMV HA hRB-wt) (gift from Steven Dowdy (Addgene plasmid 58905))107 were 
transfected with Lipofectamine 3000 Transfection Kit (Invitrogen, L3000015). PLD 
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inihibitors VU0359595 (PLD1) and VU02855655-A (PLD2) and phosphatidyl butanol 
(258637) were obtained from Avanti Polar Lipids. E2F inhibitor, HLM006474 (324461), 
was obtained from Calbiochem. [3H]-myristate (NET830005MC) was obtained from 
Perkin Elmer. 
Cell viability 
Cell viability was determined by trypan blue exclusion. After various treatments, cells 
were harvested, washed and treated with trypan blue at a concentration of 0.4% (w/v). 
After 20 minutes, trypan blue uptake was scored using a hemacytometer. 
Phospholipase D assay 
Cells were plated in 6-well plates at 2 x 105 cells per well. Cells were then prelabeled for 
4 hours with of [3H]-myristate (3 µCi; 60 Ci/mmol) in 2 ml of medium. PLD catalyzed 
transphosphatidylation for 20 minutes in the presence of 0.8% 1-butanol. Labeled media 
was removed and the cells were washed and then lysed of with 500 µl of acidified 
methanol (methanol: 6N HCl (50:2)). The cells were then added to the first extraction 
tube (155 µl 1N NaCl and 500 µl CHCl3), vortexed for 30 seconds and centrifuged for 3 
minutes at 16,100 x g. The organic phase was then transferred to the second extraction 
tube (350 µl H20, 115 µl CH3OH, and 115 µl NaCl), vortexed for 15 seconds and 
centrifuged for 3 minutes at 16,100 x g. The organic phase (350 ul), spiked with 10 µl of 
12 µM unlabeled phosphatidyl butanol to visualize, was loaded onto a silica gel thin 
layer chromatography (TLC) plate and the mobile phase (the organic phase of the 
mixture of ethyl acetate, isooctane, glacial acetic acid, and water at a 77:35:14:70 ratio) 
was allowed to proceed across the length of the TLC plate. The phosphatidyl butanol 
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band was visualized with iodine vapor and marked. The band was scraped from the 
plate and a scintillation count was performed. 
Transient transfections 
Cells were plated in 6-well plates in medium containing 10% FBS. The next day 
transfections with plasmid (1 µg/ml) in Lipofectamine 3000 or siRNAs (50 nM) in 
Lipofectamine RNAiMax were performed in the absence of serum. After 6 hours 
reagents were replaced with fresh media with 10% FBS and cells were allowed to 
incubate for an additional 48 (plasmid) to 96 hours (siRNA). 
Trans-well migration and invasion assays 
The assays were carried out using BIOCOAT™ cell culture inserts that have 
polyethylene terephthalate filters (8 um pore size on the bottom. For migration assays, 
inserts were used directly without coating (BD Bioscience 354578); for invasion assays, 
the inserts were pre-coated with Matrigel™ purified from the Engelbreth-Holm-Swarm 
mouse sarcoma, a tumor rich in extracellular matrix proteins, which closely mimics the 
basement membrane in vivo (BD Bioscience 354480). Five hundred microliters of single 
cell suspensions with a concentration of 5 x 104 cells/ml were added into the inserts. 
The inserts were set into 24-well plates that held 0.75 ml/well of growth media and 
incubated under normal growth condition for 24 hours. Cells that had not penetrated the 
filters were wiped out with cotton swabs and cells that had migrated or invaded to the 
lower surface of the filters were fixed in methanol and then stained with a 0.2% (v/v) 
solution of crystal violet in 2% (v/v) ethanol. The number of migrated or invaded cells 
was counted under the microscope. The mean of five individual fields in the center of 
the filter where migration and invasion was the highest was obtained for each well. 
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Western blot analysis 
Proteins were extracted from cultured cells in M-PER (Thermo Scientific 78501) Equal 
amounts of proteins were subjected to SDS-PAGE on polyacrylamide separating gels. 
Electrophoresed proteins were then transferred to nitrocellulose membrane. After 
transfer, membranes were blocked in an isotonic solution containing 5% non-fat dry milk 
in phosphate buffered saline. Membranes were then incubated with primary antibodies 
as described in the text. The dilutions were used as per vendor’s instructions. 
Depending on the origin of the primary antibody, either anti-mouse or anti-rabbit HRP 
conjugated IgG was used for detection using ECL system (Thermo Scientific 34080). 
Wound healing assay 
Cells were plated in 24-well plates in medium containing 10% FBS at 90% confluency. 
The next day a path was cleared through the monolayer of cells with a 200 µl pipette tip 
and the medium was replaced with fresh complete medium. Closure was then observed 
after 24 hours. Area closure was quantified using the MRI Wound Healing Tool macro 
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